News
CLDX
26.77
+2.72%
0.71
Weekly Report: what happened at CLDX last week (1125-1129)?
Weekly Report · 12/02 11:18
Weekly Report: what happened at CLDX last week (1118-1122)?
Weekly Report · 11/25 11:10
Celldex Therapeutics Initiates Phase 1a Trial for Bispecific Antibody CDX-622 Targeting Chronic Inflammation
Barchart · 11/20 17:20
Celldex announces first patient dosed in Phase 1a study of CDX-622
TipRanks · 11/20 13:15
CELLDEX THERAPEUTICS INC - SUBCUTANEOUS FORMULATION TO BE ADDED TO STUDY IN 2025
Reuters · 11/20 13:01
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
Benzinga · 11/20 12:00
Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Dow Jones · 11/20 11:21
Celldex’s Barzolvolimab: A Promising Therapy with Strong Safety and Efficacy Profile Boosts Buy Rating
TipRanks · 11/20 11:19
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Benzinga · 11/20 11:11
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
Barchart · 11/20 07:01
Celldex Therapeutics Reports Q3 2024 Progress and Financials
TipRanks · 11/20 03:55
Weekly Report: what happened at CLDX last week (1111-1115)?
Weekly Report · 11/18 11:07
Weekly Report: what happened at CLDX last week (1104-1108)?
Weekly Report · 11/11 11:19
Celldex’s Strategic Focus on Barzolvolimab Drives Buy Rating Amid Promising Clinical Advancements
TipRanks · 11/08 07:26
Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Dow Jones · 11/07 20:25
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Benzinga · 11/07 20:15
Celldex Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/07 15:09
Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)
TipRanks · 11/07 13:19
Celldex Buy Rating Affirmed Amid Strong Financials and Promising Drug Pipeline
TipRanks · 11/07 11:26
Celldex: Strong Buy Rating Amid Promising Pipeline and Attractive Valuation
TipRanks · 11/07 10:27
More
Webull provides a variety of real-time CLDX stock news. You can receive the latest news about Celldex Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.